Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.74 USD | +11.46% | +22.99% | +10.13% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.13% | 582M | |
-3.17% | 102B | |
+1.23% | 96.29B | |
+2.13% | 22.18B | |
-15.68% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.52% | 16.36B | |
+5.54% | 13.97B | |
+33.13% | 12.17B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint